Specifically, therapeutically targeting EZH2 activity not only reduces colitis-related symptoms and extends the survival of colitic mice, but, even more remarkably, this therapeutic approach also delays CAC and reduces tumor burden. The gene discussed is EZH2; the disease is colitis.